261 related articles for article (PubMed ID: 34626356)
1. Current Management and New Developments in the Treatment of ALL.
Darrah J; Sun W
Cancer Treat Res; 2021; 181():75-96. PubMed ID: 34626356
[TBL] [Abstract][Full Text] [Related]
2. Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage.
Jabbour E; Sasaki K; Ravandi F; Huang X; Short NJ; Khouri M; Kebriaei P; Burger J; Khoury J; Jorgensen J; Jain N; Konopleva M; Garcia-Manero G; Kadia T; Cortes J; Jacob J; Montalbano K; Garris R; O'Brien S; Kantarjian HM
Cancer; 2018 Oct; 124(20):4044-4055. PubMed ID: 30307611
[TBL] [Abstract][Full Text] [Related]
3. Blinatumomab or Inotuzumab Ozogamicin as Bridge to Allogeneic Stem Cell Transplantation for Relapsed or Refractory B-lineage Acute Lymphoblastic Leukemia: A Retrospective Single-Center Analysis.
Stelmach P; Wethmar K; Groth C; Wenge DV; Albring J; Mikesch JH; Schliemann C; Reicherts C; Berdel WE; Lenz G; Stelljes M
Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):e724-e733. PubMed ID: 32646833
[TBL] [Abstract][Full Text] [Related]
4. Sequencing of novel agents in relapsed/refractory B-cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia.
Badar T; Szabo A; Dinner S; Liedtke M; Burkart M; Shallis RM; Yurkiewicz IR; Kuo E; Khan MA; Balasubramanian S; Yang J; Hefazi M; Podoltsev N; Patel A; Curran E; Wang A; Arslan S; Aldoss I; Siebenaller C; Mattison RJ; Litzow MR; Wadleigh M; Advani AS; Atallah E
Cancer; 2021 Apr; 127(7):1039-1048. PubMed ID: 33259056
[TBL] [Abstract][Full Text] [Related]
5. Dismal outcomes of patients with relapsed/refractory Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia after failure of both inotuzumab ozogamicin and blinatumomab.
Short NJ; Macaron W; Konopleva M; Ravandi F; Jain N; Issa GC; Kadia T; Sasaki K; Kebriaei P; Yilmaz M; Thompson PA; Takahashi K; Abbas HA; Wierda WG; Garris R; Kantarjian HM; Jabbour E
Am J Hematol; 2022 Jun; 97(6):E201-E204. PubMed ID: 35266566
[No Abstract] [Full Text] [Related]
6. Antibody based therapy in relapsed acute lymphoblastic leukemia.
Jammal N; Chew S; Jabbour E; Kantarjian H
Best Pract Res Clin Haematol; 2020 Dec; 33(4):101225. PubMed ID: 33279181
[TBL] [Abstract][Full Text] [Related]
7. Real-world treatment patterns of novel drugs in relapsed or refractory acute lymphoblastic leukemia patients in Japan.
Moribe T; Xu L; Tajima K; Yonemoto N
Future Oncol; 2023 Jun; 19(19):1343-1356. PubMed ID: 37212792
[TBL] [Abstract][Full Text] [Related]
8. Current Approaches to Philadelphia Chromosome-Positive B-Cell Lineage Acute Lymphoblastic Leukemia: Role of Tyrosine Kinase Inhibitor and Stem Cell Transplant.
Kim K; Jabbour E; Short NJ; Kebriaei P; Kantarjian H; Ravandi F
Curr Oncol Rep; 2021 Jun; 23(8):95. PubMed ID: 34125415
[TBL] [Abstract][Full Text] [Related]
9. Matching-Adjusted Indirect Comparison of Blinatumomab vs. Inotuzumab Ozogamicin for Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia.
Song J; Ma Q; Gao W; Cong Z; Xie J; Zimmerman Z; Belton L; Franklin J; Palmer S
Adv Ther; 2019 Apr; 36(4):950-961. PubMed ID: 30758745
[TBL] [Abstract][Full Text] [Related]
10. The treatment landscape for Relapsed Refractory B Acute Lymphoblastic Leukaemia (ALL).
Sharplin KM; Marks DI
Leuk Lymphoma; 2022 Jun; 63(6):1292-1301. PubMed ID: 34991420
[TBL] [Abstract][Full Text] [Related]
11. Clinical trial update on bispecific antibodies, antibody-drug conjugates, and antibody-containing regimens for acute lymphoblastic leukemia.
Liu D; Zhao J; Song Y; Luo X; Yang T
J Hematol Oncol; 2019 Feb; 12(1):15. PubMed ID: 30736842
[TBL] [Abstract][Full Text] [Related]
12. Outcomes After Retreatment With Inotuzumab Ozogamicin for Relapsed/Refractory Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia.
Alban J; DuVall A; Gurbuxani S; Stock W; Patel AA
JCO Precis Oncol; 2022 Oct; 6():e2200353. PubMed ID: 36240471
[No Abstract] [Full Text] [Related]
13. Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome-positive relapsed/refractory acute lymphoblastic leukemia.
Stock W; Martinelli G; Stelljes M; DeAngelo DJ; Gökbuget N; Advani AS; O'Brien S; Liedtke M; Merchant AA; Cassaday RD; Wang T; Zhang H; Vandendries E; Jabbour E; Marks DI; Kantarjian HM
Cancer; 2021 Mar; 127(6):905-913. PubMed ID: 33231879
[TBL] [Abstract][Full Text] [Related]
14. Treatment with anti CD19 chimeric antigen receptor T cells after antibody-based immunotherapy in adults with acute lymphoblastic leukemia.
Danylesko I; Chowers G; Shouval R; Besser MJ; Jacoby E; Shimoni A; Nagler A; Avigdor A
Curr Res Transl Med; 2020 Jan; 68(1):17-22. PubMed ID: 31882377
[TBL] [Abstract][Full Text] [Related]
15. Inotuzumab Ozogamicin: First Global Approval.
Lamb YN
Drugs; 2017 Sep; 77(14):1603-1610. PubMed ID: 28819740
[TBL] [Abstract][Full Text] [Related]
16. Mini-hyper CVD + CRIB (condensed rituximab, inotuzumab ozogamicin, and blinatumomab) for refractory pediatric B-acute lymphoblastic leukemia.
McCall D; Jabbour E; Roth M; Nunez C; Cuglievan B
Pediatr Blood Cancer; 2023 Jan; 70(1):e29939. PubMed ID: 36031729
[TBL] [Abstract][Full Text] [Related]
17. Using immunotherapy and novel trial designs to optimise front-line therapy in adult acute lymphoblastic leukaemia: breaking with the traditions of the past.
Short NJ; Kantarjian H
Lancet Haematol; 2023 May; 10(5):e382-e388. PubMed ID: 37003279
[TBL] [Abstract][Full Text] [Related]
18. Sequential therapy with inotuzumab ozogamicin, CD19 CAR T cells, and blinatumomab in an elderly patient with relapsed acute lymphoblastic leukemia.
Wullenkord R; Reicherts C; Mikesch JH; Marx J; Wethmar K; Albring J; Call S; Lenz G; Stelljes M
Ann Hematol; 2021 Feb; 100(2):587-589. PubMed ID: 32829460
[No Abstract] [Full Text] [Related]
19. SOHO State of the Art Updates and Next Questions | Approach to Older Adults With Phildadelphia-Chromosome Negative Acute Lymphoblastic Leukemia.
Shimony S; Luskin MR
Clin Lymphoma Myeloma Leuk; 2024 Mar; 24(3):133-140. PubMed ID: 38102012
[TBL] [Abstract][Full Text] [Related]
20. Acute Lymphoblastic Leukemia and Acute Lymphoblastic Lymphoma: Same Disease Spectrum but Two Distinct Diagnoses.
Kline KAF; Kallen ME; Duong VH; Law JY
Curr Hematol Malig Rep; 2021 Oct; 16(5):384-393. PubMed ID: 34417955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
